Microbiota Modulation in Patients with Metabolic Syndrome

Area of Science:

• Microbiology
• Metabolic Disorders
• Cardiovascular Health

Background:

• Metabolic syndrome (MS) affects 25% of adults in developed countries, increasing cardiovascular disease risk.
• Diagnostic criteria for MS can vary, leading to interpretation challenges and controversies.
• Gut microbiota plays a crucial role in metabolic homeostasis, with dysbiosis observed in MS.

Purpose of the Study:

• To review recent studies on the relationship between gut microbiota and metabolic syndrome.
• To explore the therapeutic potential of probiotics and synbiotics in managing MS.

Main Methods:

• Literature review of recent scientific studies.
• Analysis of research focusing on gut microbiota composition in individuals with MS.
• Evaluation of studies investigating the effects of probiotics and synbiotics on metabolic parameters.

Main Results:

• Gut microbiome in MS is characterized by dysbiosis, with specific microbial taxa linked to metabolic alterations.
• Probiotics and synbiotics demonstrate potential in correcting gut dysbiosis and improving metabolic health.
• Emerging evidence suggests these interventions can mitigate metabolic disturbances associated with MS.

Conclusions:

• Gut microbiota modulation is a promising therapeutic strategy for metabolic syndrome.
• Probiotics and synbiotics offer potential benefits for restoring metabolic homeostasis in MS patients.
• Further research is warranted to fully elucidate the role of microbiota-targeted therapies in managing MS.